Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.45 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429156 | 0.90 | HDAC1 (0.52) | HDAC6HDAC8HDAC3HDAC1HDAC4 | |
| SCHEMBL13428572 | 0.90 | AKR1C3 (0.44) | GSK3BKDM4EHPGD | |
| SCHEMBL8190109 | 0.88 | HDAC6 (0.46) | HDAC6HDAC8HDAC3HDAC1HDAC4 | |
| SCHEMBL13428475 | 0.85 | CA12 (0.44) | HPGD | |
| SCHEMBL13429148 | 0.82 | HDAC6 (0.46) | HDAC6HDAC8HDAC3HDAC1HDAC4 | |
| SCHEMBL13428521 | 0.80 | KDM4E (0.37) | HDAC1GSK3BKDM4EHPGD | |
| SCHEMBL13428583 | 0.80 | AKR1C3 (0.46) | HDAC6HDAC1KDM4EHPGD | |
| SCHEMBL13428471 | 0.80 | CA12 (0.45) | HPGD | |
| SCHEMBL8187060 | 0.78 | HDAC1 (0.52) | HDAC6HDAC8HDAC3HDAC1HDAC4 | |
| SCHEMBL13429138 | 0.78 | KMT2A (0.48) | HDAC6HDAC8HDAC3HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC6 29/4885HDAC8 7/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.